Active Filter(s):
Details:
Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular and kidney disease.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 16, 2023
Details:
KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023